Specialized proresolving lipid mediators (SPMs) decrease human B cell IgE production: implications for allergy and asthma (HYP7P.309)

Abstract

Abstract Resolution of inflammation is a biologically active process regulated by newly identified specialized proresolving lipid mediators (SPMs). These endogenous lipid-derived mediators promote the resolution of inflammation and maintain homeostasis by regulating the immune system. Little is known about the functions of SPMs on adaptive immune cells, such as B cells. Our laboratory has discovered that certain omega-3 fatty acid derived SPMs promote human B cell IgM and IgG antibody production in vitro. Human B cells also produce IgE antibodies, which play an essential role in the onset of inflammatory diseases, such as seasonal allergies and asthma. Here, we show that certain SPMs decrease human B cell IgE production in vitro. Omega-3-derived SPMs, 17-HDHA (17-hydoxydocosahexaenoic acid) and RvD1 (resolvin D1), strongly decreased the IgE production in B cells, as well as the number of IgE-secreting cells in peripheral blood of healthy and asthmatic human donors. In addition, 17-HDHA and RvD1 also reduced IgE production by the spontaneously IgE secreting multiple myeloma B cell line, U266. These results show that SPMs are non-immunosuppressive endogenous mediators that could specifically dampen IgE production and have potential as therapeutics for asthma. Moreover, SPMs might also be effective on other IgE-mediated inflammatory diseases such as atopic dermatitis.